Skip Navigation
Keros Therapeutics logo
  • About Us
    • About Keros
    • Our Team
    • Board of Directors
    • Contact
  • Pipeline
    • Our Pipeline
    • Product Candidates
      • KER-050
      • KER-012
      • KER-065
  • Our Science
    • TGF-Beta Biology and Role in Diseases
    • Hematology Franchise
    • Pulmonary & Cardiovascular Franchise
    • Neuromuscular Franchise
    • Scientific Publications
  • Investors & Media
    • Home
    • News & Events
      • Press Releases
      • Events & Presentations
      • Scientific Publications
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQ
      • Investor Contact
      • Email Alerts
  • Patients
    • Clinical Trials
    • Patient Resources
    • Expanded Access Policy
  • Careers
    • Join Our Team
    • Benefits
    • Current Opportunities

Scientific Publications

Dec 7, 2020

KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies

62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Keros Therapeutics logo footer
  • About Us
  • Pipeline
  • Our Science
  • Patients
  • Careers
Visit us on LinkedIn

©2025 Keros Therapeutics All Rights Reserved.

  • Privacy Policy
  • Data Privacy Framework Policy
  • Terms of Use
  • Cookie Policy

You are about to leave Keros Therapeutics' website.

Keros assumes no responsibility for the information, statements or other content you may encounter on third-party websites.

Stay on Keros' siteContinue to External Site